Sugammadex, a modified cyclodextrin molecule, encapsulates rocuronium and other aminosteroid neuromuscular blocking agents (NMBAs) to provide rapid and reliable reversal of neuromuscular block. In comparison to the standard reversal agent, neostigmine, the quality and speed of reversal are impressive, reversing moderate block around 17 times faster 1 and with fewer episodes of partial reversal in recovery. 2, 3 In addition, it can provide reversal from deep blockade, 3,4 a feature not possible with neostigmine. Arguably, sugammadex is the ideal reversal agent whenever an aminosteroid NMBA is used, as it can potentially speed recovery and improve turnaround time in surgical lists. 5 Sugammadex has also been proposed as an agent to treat rocuronium-induced anaphylaxis, with isolated case reports in the literature suggesting an almost immediate reversal of the anaphylaxis cascade when sugammadex was administered. 6, 7 The main barrier to the use of sugammadex, in the majority of countries, is cost. It is up to 20 times more expensive than neostigmine at a dose of 2e4 mg kg À1 (for reversal of moderate block), and clearly even more expensive with the 16 mg kg À1 dose (for reversal of profound block). In Japan, however, the national healthcare insurance system subsidises patient care, and the cost of drugs seems only a minor consideration for anaesthetists. Here, sugammadex is used routinely, and an estimated 10% of the population received sugammadex during an 8 yr period from 2010 to 2018. 8 Another concern around the use of sugammadex is the risk of hypersensitivity. Indeed, sugammadex was only approved for use in the United States in 2015 (compared with 2008 in Europe and Australia) because of concerns about hypersensitivity. It is ironic that, as sugammadex was approved by the US Food and Drug Administration (FDA), the body of evidence of hypersensitivity to the drug in clinical settings seems to be strengthening: in Japan, sugammadex is now the leading cause of perioperative anaphylaxis. 8 Two papers in this issue of the British Journal of Anaesthesia report investigations of sugammadex hypersensitivity. 9,10 These clinical trials undertaken before FDA approval and funded by the manufacturer of sugammadex were presumably done with a view to allaying concerns about the incidence of hypersensitivity, whereas they may have had the opposite effect. Both trials involved giving sugammadex at doses of either 4 or 16 mg kg À1 , or placebo, repeated twice at weekly intervals, to healthy non-anaesthetised subjects. The aim was to establish the rate of hypersensitivity and to determine whether hypersensitivity became more likely after repeated administrations. They also sought to determine the underlying mechanism of hypersensitivity, and specifically whether this was an immunoglobulin (Ig)E-or IgG-mediated process. After completion of data collection in the first study, 9 deviations with the potential to introduce bias in the assessment of hypersensitivity were identified, and this led to the repeat study. 10 Adverse events that might represent hypersensitivity were assessed by an independent and blinded committee. The authors defined hypersensitivity as 'objectively reproducible symptoms and signs of allergic disease initiated by exposure to a defined stimulus at a dose tolerated by non-hypersensitive persons'. Anaphylaxis was further defined as 'acute onset of skin þ/e mucosal symptoms, with at least one of either respiratory, cardiovascular or neurological compromise'.
In the first study, 9 the incidence of confirmed hypersensitivity was determined to be 0.7% in the 4 mg kg À1 group, 4.7% in the 16 mg kg À1 group, and 0% in the placebo group. One of the hypersensitivity subjects in the 16 mg kg À1 group was adjudicated to have suffered anaphylaxis. In the second study, 6.6% of the 4 mg kg À1 group were judged to have experienced hypersensitivity, 9.5% of the 16 mg kg À1 group, and 1.3% of the placebo group. Again, there was a single case of anaphylaxis in the 16 mg kg À1 group.
Overall, between the two studies, amongst subjects who received at least one dose of sugammadex at either dose, there was an incidence of confirmed hypersensitivity of 5% (32/597). The incidence of anaphylaxis across all subjects given sugammadex was 0.3% (2/597). Both of the anaphylaxis cases occurred in the 16 mg kg À1 group, giving an incidence of anaphylaxis at this higher dose of 0.7% (2/298).
In six subjects (three in each study), hypersensitivity occurred on the first dosing of sugammadex; all six subjects were in the 16 mg kg À1 groups. Two were allowed to continue in the study; the remainder discontinued the study. In the two who continued, one had experienced cough and widespread urticaria, whilst the other presented with flushing, urticaria, and chest signs. Although the symptoms resolved within a few hours without treatment, there was a self-evident risk of a more severe reaction on re-exposure, which could not be excluded by the investigators. It is not clear how this risk was communicated to the subjects.
On the basis of this work, an incidence of 1:20 mild or moderate hypersensitivity reactions could be expected for each exposure to sugammadex, and around 1:150 incidence of anaphylaxis when used at a dose of 16 mg kg À1 . These are alarming rates for anaesthetists. Compared with those drugs already widely used in the perioperative period, the increased risk of anaphylaxis would seem unjustifiable. For example, succinylcholine and teicoplanin, widely recognised to be relatively common causes of allergy, have an incidence of anaphylaxis of 11/100 000 and 16/100 000, respectively. 11 However, these high rates of hypersensitivity to sugammadex do not appear to translate into clinical practice. In Japan, the incidence of hypersensitivity was calculated from a national database audit and a single-centre study, at 1:34e40 000 and 1:2500, respectively. 8 Based on the rates of confirmed anaphylaxis described in the papers by de Kam and colleagues 9 and Min and colleagues, 10 one might have expected tens of thousands of cases in Japan alone, yet only 284 cases have been reported in total. In a 1 yr study of perioperative anaphylaxis in the UK, only one confirmed case of sugammadex anaphylaxis was reported from an estimated 64 000 administrations. 11 One explanation for the apparent discrepancy between these findings is under-reporting of perioperative anaphylaxis, a problem that has been previously highlighted. 12,13 However, when new drugs are brought to market, there is a tendency to over-report adverse reactions. This was noted with rocuronium, which initially appeared to be more allergenic than other NMBAs, 14 but which has recently been demonstrated to be roughly equal to atracurium in its propensity to cause allergy. 11 It is unlikely that frequent episodes of serious allergic reactions would go largely unremarked for several years.
Another explanation is that mild or moderate cases of hypersensitivity are not deemed to be clinically relevant during the perioperative period, or not severe enough to be recognised. Hypersensitivity is not an all-or-nothing response, but displays a spectrum of severity. Milder cases can manifest in the awake patient as feeling unwell, itchy, or anxious; these symptoms will be missed in anaesthetised patients. Objective signs, such as tachycardia, flushing, or mild bronchospasm, may be attributed to the effects of anaesthesia and airway manipulation, or be physically obscured by surgical drapes. It is also possible that the now routine use of dexamethasone as an anti-emetic further reduces the severity of hypersensitivity. However, general anaesthesia provides many of the cofactors, which are thought to worsen or precipitate anaphylaxis (and, in particular, non-allergic anaphylaxis). The co-administration of several large and complex molecules, effects of surgical and emotional stress, heat, and concurrent infection can all act to destabilise mast cells and produce systemic histamine release. It would be reasonable to think that the cough seen in an awake subject given sugammadex may manifest in the anaesthetised patient as profound airway irritation and is likely to be exacerbated by airway manipulation. This would mean that general anaesthesia would increase, not decrease, the risk of hypersensitivity. The severity of hypersensitivity reactions is essentially unpredictable, and the likelihood of reactions, which are apparently mild in a research setting, translating into severe reactions clinically, is unknown. Studies of food and venom allergy indicate that the severity of reactions cannot be reliably predicted on the basis of previous reactions, or time elapsed since. 15e17 We should be neither falsely reassured by the apparent mildness of most reactions nor too alarmed by the rate of reactions in these two studies, as it remains unclear how this translates into clinical practice. We do, however, find it hard to agree with the implication that the greater risk of anaphylaxis when higher doses are used is mitigated by the immediate availability of an anaesthetist and resuscitation equipment. 10 The onset of anaphylaxis during any anaesthetic is a critical event with associated morbidity and mortality. The need for higher doses of sugammadex is most likely to arise in already fraught clinical scenarios (e.g. the failed rapid sequence induction); anaphylaxis as an additional critical event could be overwhelming for both patient and anaesthetist regardless of the proximity of key personnel and equipment.
Our understanding of the likelihood of harmful hypersensitivity reactions might be helped by elucidating the underlying mechanisms, and de Kam and colleagues 9 and Min and colleagues 10 have performed exploratory work on this. To the best of our knowledge, there is no other mechanistic work in this area. First, they looked for evidence of mast-cell degranulation, through serial serum mast-cell-tryptase (MCT) measurements. None of the subjects demonstrated a dynamic change in MCT, including the two with confirmed anaphylaxis. This raises the possibility of a mechanism for the clinical picture of anaphylaxis not involving mast-cell degranulation.
Possibilities include complement-or basophil-mediated mechanisms, or other non-elucidated mechanisms. Alternatively, an increase in MCT was not seen because the reaction was not severe enough to generate this, or the MCT results were falsely negative. MCT is not 100% sensitive, 18 and negative results do not preclude a diagnosis of anaphylaxis.
Evidence of IgE (or IgG) sensitisation in subjects with and without clinical evidence of hypersensitivity was also sought by de Kam and colleagues 9 and Min and colleagues 10 using assays for sugammadex-specific IgE or IgG antibodies, and skin testing. Skin testing, in the presence of appropriate negative and positive controls, suggests a specific IgE-mediated effect against the compound being tested. Neither serum nor skintest evidence of anti-sugammadex antibodies 'proves' allergy, as not all patients with specific antibodies will exhibit a clinical picture of allergy on exposure. 19 Both testing modalities lack reproducibility, and neither has 100% specificity or sensitivity. For many drugs, the negative predictive value of these tests is low and the positive predictive value is not 100%. 20 Further work is needed to validate skin and serum testing for sugammadex antibodies before conclusions about these results can be drawn. The papers by de Kam and colleagues 9 and Min and colleagues 10 also describe basophil activation testing (BAT) as a marker of hypersensitivity, and studies to determine whether complement or contact activation had occurred. These are largely research tools, although there is some evidence from Japan for the clinical utility of BAT. 21 In conclusion, the work presented by de Kam and colleagues 9 and Min and colleagues 10 leaves us with perhaps more questions than answers. The discrepancy between their findings of high rates of hypersensitivity, and the clinical evidence for perioperative hypersensitivity, remains difficult to rationalise. There is undisputed evidence of an allergy risk with sugammadex, but it is too early to quantify that risk precisely. However, on the basis of current knowledge, it would at least be prudent to avoid the use of sugammadex in the treatment of suspected rocuronium allergy. Administration of a potentially highly allergenic drug, to treat an ongoing anaphylaxis, seems at very best a triumph of hope over evidence.
As the pricing structure of sugammadex changes, we are likely to see a significant expansion in its use. With this, predictably, will be an increase in severe adverse reactions. What remains unknown is whether this will be at the rates predicted by de Kam and colleagues 9 and Min and colleagues. 
New findings about PACU length of stay
Previous studies have examined factors influencing time that patients spend in the PACU. 2 The authors' unique observation is that PACU length of stay differs by time of day among children undergoing brain imaging, particularly among children older than 5 yr (their Fig. 6D ). 1 They performed multiple subgroup tests, and provide details of their PACU, 1 that suggest that the findings reflect a biological, circadian effect. 1 Nevertheless, whether this explains their findings will require confirmation by other investigators. Regardless, the mechanism of the time-of-day variation in PACU length of stay is not relevant to the topic of this editorial; rather, we focus on the effect of this phenomenon on PACU nurse staffing. The mechanism is irrelevant for staffing considerations because the children present received nursing care and the length of stay did vary by time of day. 1 In the more than a dozen PACU studies performed by our research group, and in our review of dozens of manuscripts by other authors, we have no recollection of circadian variation in length of stay having been addressed by us or other reviewers.
Evidence-based management studies of PACU staffing
When considering the effect of time-of-day variation in phase I length of stay on PACU staffing, one needs to limit consideration to evidence-based management studies. The reason is that some hospitals and outpatient facilities try to plan fixed ratios of PACU beds per operating room (OR) (e.g. 1.5 to 1). Differences in the predicted length of stay for patients would not affect staffing, because PACU length of stay does not change the number of ORs. However, simplistic ratios like that are not based on managerial epidemiology studies. 3 The ratios lack validity (face, concurrent, predictive, and convergent) other than for purposes of making comparisons among facilities differing several-fold in numbers of ORs. 2,4e6 Appropriate PACU staffing depends, at a minimum, on the following factors: (i) mean duration of the daily operating room schedule, (ii) number of patients admitted to the PACU, (iii) patient acuity and their corresponding nurse/patient ratio, (iv) PACU length of stay for patients undergoing different types of anaesthetics, and (v) percentage of patients who can entirely bypass the level I PACU (e.g. after monitored anaesthesia care). 2,4e6 Influence of time-of-day variation in length of stay on simulation of PACU staffing needs One way to plan PACU staffing is through computer simulation of the inflow and outflow of patients. The earliest published computer simulation of the flow of patients from ORs to PACU of which we are aware is by Kwak and colleagues 7 in 1976. Each surgical specialty's cases had a probability distribution for time in the OR and time in the PACU. 7 Months in advance, when PACU staffing decisions are made, the individual surgical cases DOI of original article: doi: 10.1016/j.bja.2018.06.027.
